Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent

Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure simila...

Full description

Saved in:
Bibliographic Details
Published inDrugs (New York, N.Y.) Vol. 80; no. 3; pp. 285 - 313
Main Authors Zhanel, George G., Esquivel, Jenine, Zelenitsky, Sheryl, Lawrence, Courtney K., Adam, Heather J., Golden, Alyssa, Hink, Rachel, Berry, Liam, Schweizer, Frank, Zhanel, Michael A., Bay, Denice, Lagacé-Wiens, Philippe R. S., Walkty, Andrew J., Lynch, Joseph P., Karlowsky, James A.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.02.2020
Springer Nature B.V
Subjects
Administration, Intravenous
Administration, Oral
Animal models
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacology
Antibacterial activity
Antibiotic resistance
Antibiotics
Bacteria
Binding
Bioavailability
Bronchopulmonary infection
Clinical trials
Community-Acquired Infections - drug therapy
Comparators
Cystitis
Drug resistance
Efflux
FDA approval
Gram-Negative Bacteria - drug effects
Gram-Positive Bacteria - drug effects
Humans
Internal Medicine
Intravenous administration
Intravenous infusion
Linezolid
Medicine
Medicine & Public Health
Methicillin
Minimum inhibitory concentration
Minocycline
Moxifloxacin
Neutropenia
Oral administration
Organic chemistry
Pathogens
Patients
Pharmacodynamics
Pharmacokinetics
Pharmacology
Pharmacology/Toxicology
Pharmacotherapy
Pneumonia
Protein biosynthesis
Protein synthesis
Proteins
Pyelonephritis
Review Article
Rings (mathematics)
Side effects
Skin
Skin Diseases, Bacterial - drug therapy
Staphylococcus aureus
Staphylococcus infections
Streptococcus infections
Tetracyclines
Tetracyclines - administration & dosage
Tetracyclines - pharmacology
Therapy
Thigh
Tigecycline
United States > US
Online AccessGet full text

Cover

Abstract Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Omadacycline remains active against bacterial isolates possessing common tetracycline resistance mechanisms such as efflux pumps (e.g., TetK) and ribosomal protection proteins (e.g., TetM) as well as in the presence of resistance mechanisms to other antibiotic classes. The pharmacokinetics of omadacycline are best described by a linear, three-compartment model following a zero-order intravenous infusion or first-order oral administration with transit compartments to account for delayed absorption. Omadacycline has a volume of distribution ( V d ) ranging from 190 to 204 L, a terminal elimination half-life ( t ½ ) of 13.5–17.1 h, total clearance (CL T ) of 8.8–10.6 L/h, and protein binding of 21.3% in healthy subjects. Oral bioavailability of omadacycline is estimated to be 34.5%. A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration ( C max ) of 0.5–0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC 0–∞ ) of 9.6–11.9 mg h/L. The free plasma area under concentration–time curve divided by the minimum inhibitory concentration (i.e., f AUC 24h /MIC), has been established as the pharmacodynamic parameter predictive of omadacycline antibacterial efficacy. Several animal models including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model have documented the in vivo antibacterial efficacy of omadacycline. A phase II clinical trial on complicated skin and skin structure infection (cSSSI) and three phase III clinical trials on ABSSSI and CABP demonstrated the safety and efficacy of omadacycline. The phase III trials, OASIS-1 (ABSSSI), OASIS-2 (ABSSSI), and OPTIC (CABP), established non-inferiority of omadacycline to linezolid (OASIS-1, OASIS-2) and moxifloxacin (OPTIC), respectively. Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. Phase II clinical trials involving patients with acute cystitis and acute pyelonephritis are in progress. Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profile of omadacycline is similar to studied comparators, linezolid and moxifloxacin. Unlike tigecycline and eravacycline, omadacycline has an oral formulation that allows for step-down therapy from the intravenous formulation, potentially facilitating earlier hospital discharge, outpatient therapy, and cost savings. Omadacycline has a potential role as part of an antimicrobial stewardship program in the treatment of patients with infections caused by antibiotic-resistant and multidrug-resistant Gram-positive [including methicillin-resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens.
AbstractList Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Omadacycline remains active against bacterial isolates possessing common tetracycline resistance mechanisms such as efflux pumps (e.g., TetK) and ribosomal protection proteins (e.g., TetM) as well as in the presence of resistance mechanisms to other antibiotic classes. The pharmacokinetics of omadacycline are best described by a linear, three-compartment model following a zero-order intravenous infusion or first-order oral administration with transit compartments to account for delayed absorption. Omadacycline has a volume of distribution ( V d ) ranging from 190 to 204 L, a terminal elimination half-life ( t ½ ) of 13.5–17.1 h, total clearance (CL T ) of 8.8–10.6 L/h, and protein binding of 21.3% in healthy subjects. Oral bioavailability of omadacycline is estimated to be 34.5%. A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration ( C max ) of 0.5–0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC 0–∞ ) of 9.6–11.9 mg h/L. The free plasma area under concentration–time curve divided by the minimum inhibitory concentration (i.e., f AUC 24h /MIC), has been established as the pharmacodynamic parameter predictive of omadacycline antibacterial efficacy. Several animal models including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model have documented the in vivo antibacterial efficacy of omadacycline. A phase II clinical trial on complicated skin and skin structure infection (cSSSI) and three phase III clinical trials on ABSSSI and CABP demonstrated the safety and efficacy of omadacycline. The phase III trials, OASIS-1 (ABSSSI), OASIS-2 (ABSSSI), and OPTIC (CABP), established non-inferiority of omadacycline to linezolid (OASIS-1, OASIS-2) and moxifloxacin (OPTIC), respectively. Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. Phase II clinical trials involving patients with acute cystitis and acute pyelonephritis are in progress. Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profile of omadacycline is similar to studied comparators, linezolid and moxifloxacin. Unlike tigecycline and eravacycline, omadacycline has an oral formulation that allows for step-down therapy from the intravenous formulation, potentially facilitating earlier hospital discharge, outpatient therapy, and cost savings. Omadacycline has a potential role as part of an antimicrobial stewardship program in the treatment of patients with infections caused by antibiotic-resistant and multidrug-resistant Gram-positive [including methicillin-resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens.
Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Omadacycline remains active against bacterial isolates possessing common tetracycline resistance mechanisms such as efflux pumps (e.g., TetK) and ribosomal protection proteins (e.g., TetM) as well as in the presence of resistance mechanisms to other antibiotic classes. The pharmacokinetics of omadacycline are best described by a linear, three-compartment model following a zero-order intravenous infusion or first-order oral administration with transit compartments to account for delayed absorption. Omadacycline has a volume of distribution (V ) ranging from 190 to 204 L, a terminal elimination half-life (t ) of 13.5-17.1 h, total clearance (CL ) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects. Oral bioavailability of omadacycline is estimated to be 34.5%. A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (C ) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC ) of 9.6-11.9 mg h/L. The free plasma area under concentration-time curve divided by the minimum inhibitory concentration (i.e., fAUC /MIC), has been established as the pharmacodynamic parameter predictive of omadacycline antibacterial efficacy. Several animal models including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model have documented the in vivo antibacterial efficacy of omadacycline. A phase II clinical trial on complicated skin and skin structure infection (cSSSI) and three phase III clinical trials on ABSSSI and CABP demonstrated the safety and efficacy of omadacycline. The phase III trials, OASIS-1 (ABSSSI), OASIS-2 (ABSSSI), and OPTIC (CABP), established non-inferiority of omadacycline to linezolid (OASIS-1, OASIS-2) and moxifloxacin (OPTIC), respectively. Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. Phase II clinical trials involving patients with acute cystitis and acute pyelonephritis are in progress. Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profile of omadacycline is similar to studied comparators, linezolid and moxifloxacin. Unlike tigecycline and eravacycline, omadacycline has an oral formulation that allows for step-down therapy from the intravenous formulation, potentially facilitating earlier hospital discharge, outpatient therapy, and cost savings. Omadacycline has a potential role as part of an antimicrobial stewardship program in the treatment of patients with infections caused by antibiotic-resistant and multidrug-resistant Gram-positive [including methicillin-resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens.
Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Omadacycline remains active against bacterial isolates possessing common tetracycline resistance mechanisms such as efflux pumps (e.g., TetK) and ribosomal protection proteins (e.g., TetM) as well as in the presence of resistance mechanisms to other antibiotic classes. The pharmacokinetics of omadacycline are best described by a linear, three-compartment model following a zero-order intravenous infusion or first-order oral administration with transit compartments to account for delayed absorption. Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects. Oral bioavailability of omadacycline is estimated to be 34.5%. A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L. The free plasma area under concentration-time curve divided by the minimum inhibitory concentration (i.e., fAUC24h/MIC), has been established as the pharmacodynamic parameter predictive of omadacycline antibacterial efficacy. Several animal models including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model have documented the in vivo antibacterial efficacy of omadacycline. A phase II clinical trial on complicated skin and skin structure infection (cSSSI) and three phase III clinical trials on ABSSSI and CABP demonstrated the safety and efficacy of omadacycline. The phase III trials, OASIS-1 (ABSSSI), OASIS-2 (ABSSSI), and OPTIC (CABP), established non-inferiority of omadacycline to linezolid (OASIS-1, OASIS-2) and moxifloxacin (OPTIC), respectively. Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. Phase II clinical trials involving patients with acute cystitis and acute pyelonephritis are in progress. Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profile of omadacycline is similar to studied comparators, linezolid and moxifloxacin. Unlike tigecycline and eravacycline, omadacycline has an oral formulation that allows for step-down therapy from the intravenous formulation, potentially facilitating earlier hospital discharge, outpatient therapy, and cost savings. Omadacycline has a potential role as part of an antimicrobial stewardship program in the treatment of patients with infections caused by antibiotic-resistant and multidrug-resistant Gram-positive [including methicillin-resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens.Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Omadacycline remains active against bacterial isolates possessing common tetracycline resistance mechanisms such as efflux pumps (e.g., TetK) and ribosomal protection proteins (e.g., TetM) as well as in the presence of resistance mechanisms to other antibiotic classes. The pharmacokinetics of omadacycline are best described by a linear, three-compartment model following a zero-order intravenous infusion or first-order oral administration with transit compartments to account for delayed absorption. Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects. Oral bioavailability of omadacycline is estimated to be 34.5%. A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L. The free plasma area under concentration-time curve divided by the minimum inhibitory concentration (i.e., fAUC24h/MIC), has been established as the pharmacodynamic parameter predictive of omadacycline antibacterial efficacy. Several animal models including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model have documented the in vivo antibacterial efficacy of omadacycline. A phase II clinical trial on complicated skin and skin structure infection (cSSSI) and three phase III clinical trials on ABSSSI and CABP demonstrated the safety and efficacy of omadacycline. The phase III trials, OASIS-1 (ABSSSI), OASIS-2 (ABSSSI), and OPTIC (CABP), established non-inferiority of omadacycline to linezolid (OASIS-1, OASIS-2) and moxifloxacin (OPTIC), respectively. Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. Phase II clinical trials involving patients with acute cystitis and acute pyelonephritis are in progress. Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profile of omadacycline is similar to studied comparators, linezolid and moxifloxacin. Unlike tigecycline and eravacycline, omadacycline has an oral formulation that allows for step-down therapy from the intravenous formulation, potentially facilitating earlier hospital discharge, outpatient therapy, and cost savings. Omadacycline has a potential role as part of an antimicrobial stewardship program in the treatment of patients with infections caused by antibiotic-resistant and multidrug-resistant Gram-positive [including methicillin-resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens.
Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Omadacycline remains active against bacterial isolates possessing common tetracycline resistance mechanisms such as efflux pumps (e.g., TetK) and ribosomal protection proteins (e.g., TetM) as well as in the presence of resistance mechanisms to other antibiotic classes. The pharmacokinetics of omadacycline are best described by a linear, three-compartment model following a zero-order intravenous infusion or first-order oral administration with transit compartments to account for delayed absorption. Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance ( CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects. Oral bioavailability of omadacycline is estimated to be 34.5%. A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC 0-∞) of 9.6-11.9 mg h/L. The free plasma area under concentration-time curve divided by the minimum inhibitory concentration (i.e., fAUC24h/MIC), has been established as the pharmacodynamic parameter predictive of omadacycline antibacterial efficacy. Several animal models including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model have documented the in vivo antibacterial efficacy of omadacycline. A phase II clinical trial on complicated skin and skin structure infection (cSSSI) and three phase III clinical trials on ABSSSI and CABP demonstrated the safety and efficacy of omadacycline. The phase III trials, OASIS-1 (ABSSSI), OASIS-2 (ABSSSI), and OPTIC (CABP), established non-inferiority of omadacycline to linezolid (OASIS-1, OASIS-2) and moxifloxacin (OPTIC), respectively. Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. Phase II clinical trials involving patients with acute cystitis and acute pyelonephritis are in progress. Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profile of omadacycline is similar to studied comparators, linezolid and moxifloxacin. Unlike tigecycline and eravacycline, omadacycline has an oral formulation that allows for step-down therapy from the intravenous formulation, potentially facilitating earlier hospital discharge, outpatient therapy, and cost savings. Omadacycline has a potential role as part of an antimicrobial stewardship program in the treatment of patients with infections caused by antibiotic-resistant and multidrugresistant Gram-positive [including methicillin-resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens.
Author Walkty, Andrew J.
Zhanel, George G.
Lawrence, Courtney K.
Bay, Denice
Esquivel, Jenine
Zelenitsky, Sheryl
Berry, Liam
Karlowsky, James A.
Zhanel, Michael A.
Hink, Rachel
Schweizer, Frank
Lynch, Joseph P.
Adam, Heather J.
Golden, Alyssa
Lagacé-Wiens, Philippe R. S.
Author_xml – sequence: 1
  givenname: George G.
  surname: Zhanel
  fullname: Zhanel, George G.
  email: ggzhanel@pcs.mb.ca
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Clinical Microbiology, Health Sciences Centre
– sequence: 2
  givenname: Jenine
  surname: Esquivel
  fullname: Esquivel, Jenine
  organization: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba
– sequence: 3
  givenname: Sheryl
  surname: Zelenitsky
  fullname: Zelenitsky, Sheryl
  organization: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba
– sequence: 4
  givenname: Courtney K.
  surname: Lawrence
  fullname: Lawrence, Courtney K.
  organization: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba
– sequence: 5
  givenname: Heather J.
  surname: Adam
  fullname: Adam, Heather J.
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Diagnostic Services, Shared Health
– sequence: 6
  givenname: Alyssa
  surname: Golden
  fullname: Golden, Alyssa
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba
– sequence: 7
  givenname: Rachel
  surname: Hink
  fullname: Hink, Rachel
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba
– sequence: 8
  givenname: Liam
  surname: Berry
  fullname: Berry, Liam
  organization: Department of Chemistry, Faculty of Science, University of Manitoba
– sequence: 9
  givenname: Frank
  surname: Schweizer
  fullname: Schweizer, Frank
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Department of Chemistry, Faculty of Science, University of Manitoba
– sequence: 10
  givenname: Michael A.
  surname: Zhanel
  fullname: Zhanel, Michael A.
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba
– sequence: 11
  givenname: Denice
  surname: Bay
  fullname: Bay, Denice
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba
– sequence: 12
  givenname: Philippe R. S.
  surname: Lagacé-Wiens
  fullname: Lagacé-Wiens, Philippe R. S.
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Diagnostic Services, Shared Health
– sequence: 13
  givenname: Andrew J.
  surname: Walkty
  fullname: Walkty, Andrew J.
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Diagnostic Services, Shared Health
– sequence: 14
  givenname: Joseph P.
  surname: Lynch
  fullname: Lynch, Joseph P.
  organization: Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, The David Geffen School of Medicine at UCLA
– sequence: 15
  givenname: James A.
  surname: Karlowsky
  fullname: Karlowsky, James A.
  organization: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Diagnostic Services, Shared Health
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31970713$$D View this record in MEDLINE/PubMed
BookMark eNp9kctKAzEUhoMoWi8v4EIG3LgZzW0mjbtBvIHYja5DJjlqZCbRJC307U1tRXDhKpzwfYef8--jbR88IHRM8DnBWFwkjmnb1JjiGhPaiJpvoQkhQtZENngbTXD5rtu2FXtoP6X31SgbuYv2GJECC8Im6HE2aqvN0gzOw2XVVY9hAUM1i3qotLfVvc9RL8CHeaq60fkwQn5bDhuh6nx2vQvZmap7BZ8P0c6LHhIcbd4D9Hxz_XR1Vz_Mbu-vuofaMNHkWlsjKANKtWyZIaw1BojlfdMLgw0ICZz3wCiXWFrDtJWaUCKs7pmxzHB2gM7Wez9i-JxDymp0ycAwaA8lqqKMc0olwbKgp3_Q9zCPvqQrVEslnhI-LdTJhpr3I1j1Ed2o41L9XKoA0zVgYkgpwosyLuvswupAblAEq1Upal2KKqWo71LUKiz9o_5s_1diaykV2L9C_I39j_UFJl6dmA
CitedBy_id crossref_primary_10_1016_j_tetlet_2024_155366
crossref_primary_10_2147_IDR_S352932
crossref_primary_10_1128_aac_01864_24
crossref_primary_10_1016_j_ejps_2024_106713
crossref_primary_10_1016_j_talanta_2022_124201
crossref_primary_10_3389_fcimb_2023_1243457
crossref_primary_10_1016_j_intimp_2024_111997
crossref_primary_10_1002_phar_2625
crossref_primary_10_1016_j_tube_2024_102482
crossref_primary_10_1080_17425255_2023_2261376
crossref_primary_10_1128_AAC_01704_21
crossref_primary_10_12968_hmed_2024_0381
crossref_primary_10_3390_microorganisms9040730
crossref_primary_10_1128_cmr_00121_23
crossref_primary_10_3138_jammi_2020_0043
crossref_primary_10_3390_antibiotics12040690
crossref_primary_10_2147_IDR_S338987
crossref_primary_10_3390_pharmaceutics13122085
crossref_primary_10_3390_antibiotics12040761
crossref_primary_10_5937_Galmed2305014S
crossref_primary_10_5937_medi57_49267
crossref_primary_10_2147_IDR_S500982
crossref_primary_10_1128_msphere_00381_24
crossref_primary_10_1093_jacamr_dlac009
crossref_primary_10_1021_acsptsci_4c00183
crossref_primary_10_1080_14787210_2023_2174100
crossref_primary_10_1128_spectrum_01289_23
crossref_primary_10_1097_QCO_0000000000000708
crossref_primary_10_22456_1679_9216_140364
crossref_primary_10_1016_j_clinmicnews_2023_04_001
crossref_primary_10_1021_acs_jmedchem_2c01629
crossref_primary_10_1063_5_0231391
crossref_primary_10_12998_wjcc_v10_i8_2550
crossref_primary_10_3389_fmicb_2022_1043736
crossref_primary_10_1080_14740338_2024_2359615
crossref_primary_10_1128_msphere_00671_24
crossref_primary_10_1007_s10096_021_04296_1
crossref_primary_10_1007_s40121_024_01057_3
crossref_primary_10_5005_jp_journals_11003_0124
crossref_primary_10_1038_s41429_024_00801_8
crossref_primary_10_3389_fcimb_2023_1244398
crossref_primary_10_3389_fmicb_2024_1408443
crossref_primary_10_1007_s00108_023_01567_1
crossref_primary_10_1016_j_biopha_2024_117666
crossref_primary_10_2174_1570180820666230224112505
crossref_primary_10_1128_Spectrum_01440_21
crossref_primary_10_1016_j_jics_2024_101303
crossref_primary_10_3390_microorganisms12071353
crossref_primary_10_1128_AAC_00709_21
crossref_primary_10_2147_IDR_S384296
crossref_primary_10_3389_fphar_2025_1559857
crossref_primary_10_1128_msphere_00665_22
crossref_primary_10_1007_s40121_024_01065_3
crossref_primary_10_1186_s13756_021_00985_w
crossref_primary_10_1093_cid_ciac591
crossref_primary_10_1128_aac_01686_23
crossref_primary_10_1016_j_diagmicrobio_2020_115129
crossref_primary_10_1128_spectrum_03654_22
crossref_primary_10_1080_07853890_2022_2085881
crossref_primary_10_2147_IMCRJ_S498539
crossref_primary_10_1128_jcm_00174_23
crossref_primary_10_3390_biom14070783
crossref_primary_10_1016_j_ejmech_2025_117267
crossref_primary_10_1080_14740338_2024_2392865
crossref_primary_10_1128_AAC_00698_20
crossref_primary_10_2174_1570193X19666211221150119
crossref_primary_10_3390_antibiotics12060953
crossref_primary_10_1016_j_idc_2020_10_003
crossref_primary_10_1093_jac_dkad174
crossref_primary_10_3390_molecules28041762
crossref_primary_10_1016_j_jgar_2024_04_004
crossref_primary_10_1016_j_vascn_2024_107503
crossref_primary_10_1038_s41429_022_00538_2
crossref_primary_10_1016_j_clinthera_2024_06_014
crossref_primary_10_1097_QCO_0000000000001089
crossref_primary_10_3389_fmed_2023_1207534
crossref_primary_10_1093_ofid_ofac591
crossref_primary_10_3390_pathogens9070522
crossref_primary_10_1093_jac_dkaa538
crossref_primary_10_12998_wjcc_v12_i25_5832
crossref_primary_10_1016_j_jmsacl_2024_11_001
crossref_primary_10_2147_IMCRJ_S473469
crossref_primary_10_3390_antibiotics13040328
crossref_primary_10_1007_s40261_022_01119_9
crossref_primary_10_2147_IDR_S437100
crossref_primary_10_5582_bst_2021_01342
crossref_primary_10_15585_mmwr_rr7206a1
crossref_primary_10_1099_jmm_0_001592
crossref_primary_10_3390_antibiotics9120905
crossref_primary_10_1186_s44280_025_00072_4
crossref_primary_10_1093_jac_dkac030
Cites_doi 10.1016/j.diagmicrobio.2010.08.023
10.1128/AAC.01734-16
10.1016/j.bmc.2016.07.029
10.1128/AAC.00018-17
10.1097/00007691-198206000-00001
10.1128/AAC.01536-15
10.1128/AAC.02057-17
10.1128/AAC.00624-19
10.1093/jac/dki197
10.1128/AAC.02411-16
10.1128/AAC.02083-18
10.1016/j.diagmicrobio.2017.05.004
10.1128/AAC.00047-18
10.1111/j.1742-1241.2006.01188.x
10.26226/morressier.56d6be7ad462b80296c97dee
10.1007/s00018-009-0172-6
10.1128/AAC.02368-16
10.1128/AAC.02262-18
10.1016/j.jinf.2010.03.024
10.1128/AAC.02434-16
10.1021/acsinfecdis.8b00349
10.1093/jac/dkm213
10.1016/j.diagmicrobio.2017.10.010
10.1016/j.ijantimicag.2018.01.006
10.1128/AAC.00948-12
10.1093/cid/ciz398
10.1128/AAC.01135-17
10.1111/j.1749-6632.2011.06354.x
10.1128/AAC.02327-17
10.3390/ph12020063
10.1128/AAC.02551-17
10.1016/j.diagmicrobio.2018.11.010
10.1586/14787210.4.1.9
10.1093/cid/ciz242
10.1128/CMR.00002-11
10.1093/cid/ciz395
10.1128/AAC.40.1.212
10.1093/ofid/ofy263
10.1016/j.femsle.2005.02.034
10.26226/morressier.56d6be7ad462b80296c97ddc
10.1093/ofid/ofy210.1208
10.1016/j.jgar.2019.02.017
10.1093/jac/dkz267
10.1128/AAC.01393-16
10.1111/j.1749-6632.2011.06323.x
10.1179/joc.2005.17.Supplement-1.5
10.1002/jcph.814
10.1007/s40265-016-0545-8
10.1177/1060028019850173
10.2165/00003495-200464010-00005
10.1016/j.diagmicrobio.2018.01.019
10.2165/0003495-200868180-00008
10.3390/antibiotics5040032
10.1080/00498254.2016.1213465
10.1056/NEJMoa1800170
10.1093/cid/ciz397
10.2217/fmb-2016-0100
10.1093/cid/ciz394
10.1177/1060028018818094
10.1517/13543784.2014.965253
10.1093/cid/ciz309
10.1016/j.ijantimicag.2009.06.021
10.1128/AAC.01784-16
10.1016/j.diagmicrobio.2016.10.022
10.1128/MMBR.65.2.232-260.2001
10.1093/cid/ciz396
10.1128/AAC.01242-13
10.1201/9781498747967
10.1515/hsz-2013-0292
10.1128/AAC.01066-13
10.5301/ijao.5000027
10.1016/S1473-3099(19)30275-0
10.1128/AAC.02522-18
10.1056/NEJMoa1800201
10.1086/431672
10.1128/AAC.00470-19
10.1128/AAC.01487-17
10.1016/j.jiph.2009.10.001
ContentType Journal Article
Copyright Springer Nature Switzerland AG 2020
Copyright Springer Nature B.V. Feb 2020
Copyright_xml – notice: Springer Nature Switzerland AG 2020
– notice: Copyright Springer Nature B.V. Feb 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
4T-
7QO
7RV
7TK
7U7
7U9
7X7
7XB
88E
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
BENPR
C1K
CCPQU
FR3
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
DOI 10.1007/s40265-020-01257-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Docstoc
Biotechnology Research Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database (Proquest)
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
Toxicology Abstracts
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Docstoc
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Technology Research Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1179-1950
EndPage 313
ExternalDocumentID 31970713
10_1007_s40265_020_01257_4
Genre Journal Article
Review
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID ---
-5G
-BR
-EM
.55
.GJ
.XZ
04C
0R~
0VX
29G
2JY
34G
36B
39C
3O-
3V.
4.4
406
53G
5GY
5RE
6I2
6PF
7RV
7X7
88E
8FI
8FJ
8R4
8R5
95.
AAAUJ
AABHQ
AACDK
AADNT
AAIAL
AAIKX
AAJKR
AAKAS
AASML
AATNV
AAWTL
AAYQN
AAYTO
AAYZH
ABAKF
ABCQX
ABDZT
ABFTV
ABIPD
ABJNI
ABJOX
ABKCH
ABKMS
ABKTR
ABPLI
ABTKH
ABTMW
ABUWG
ABUWZ
ABWHX
ABXPI
ACAOD
ACCOQ
ACCUX
ACDTI
ACGFS
ACHVE
ACIWK
ACMLO
ACPIV
ACPRK
ACZOJ
ADBBV
ADFZG
ADHHG
ADINQ
ADKPE
ADQRH
ADRFC
ADURQ
ADZCM
ADZKW
AEBJR
AEBTG
AEFQL
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AEYRQ
AFALF
AFBBN
AFFNX
AFJLC
AFKRA
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGQEE
AGQMX
AGRTI
AHBYD
AHIZS
AHMBA
AHSBF
AIAKS
AIGIU
AILAN
AIZAD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AN0
ASPBG
AUKKA
AVWKF
AWSVR
AXYYD
AZFZN
A~4
BENPR
BGNMA
BKEYQ
BNQBC
BPHCQ
BVXVI
BYPQX
CAG
CCPQU
COF
CS3
DCUDU
DPUIP
DU5
EBLON
EBS
ECV
EIHBH
EJD
ESX
EX3
F5P
FIGPU
FLLZZ
FNLPD
FSGXE
FYUFA
HF~
HMCUK
IAO
IEA
IHR
IMOTQ
INH
INR
ITC
IWAJR
J-C
JZLTJ
L7B
LLZTM
M1P
M4Y
N4W
NAPCQ
NQJWS
NU0
OAC
OPC
OVD
P2P
PCD
PQQKQ
PROAC
PSQYO
Q2X
RKO
ROL
RSV
RXW
RZALA
SISQX
SJN
SJYHP
SNPRN
SOHCF
SOJ
SPKJE
SRMVM
SSLCW
TEORI
TSG
U9L
UG4
UKHRP
UTJUX
VDBLX
VFIZW
W48
WAF
WOW
WQ9
X7M
Y6R
YFH
Z0Y
Z7U
ZGI
ZXP
~JE
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
4T-
7QO
7TK
7U7
7U9
7XB
8FD
8FK
ABRTQ
C1K
FR3
H94
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
ID FETCH-LOGICAL-c375t-adc723e22a963c136cce1d4b5b7c0ce79e44be324909dc3ad9a1217dab3cd3c43
IEDL.DBID 7X7
ISSN 0012-6667
1179-1950
IngestDate Fri Jul 11 05:35:49 EDT 2025
Sat Jul 26 02:27:21 EDT 2025
Wed Feb 19 02:29:19 EST 2025
Thu Apr 24 23:04:39 EDT 2025
Tue Jul 01 03:46:22 EDT 2025
Fri Feb 21 02:28:39 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-adc723e22a963c136cce1d4b5b7c0ce79e44be324909dc3ad9a1217dab3cd3c43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMID 31970713
PQID 2362908148
PQPubID 34797
PageCount 29
ParticipantIDs proquest_miscellaneous_2344229109
proquest_journals_2362908148
pubmed_primary_31970713
crossref_citationtrail_10_1007_s40265_020_01257_4
crossref_primary_10_1007_s40265_020_01257_4
springer_journals_10_1007_s40265_020_01257_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20200200
2020-02-00
2020-Feb
20200201
PublicationDateYYYYMMDD 2020-02-01
PublicationDate_xml – month: 2
  year: 2020
  text: 20200200
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: New Zealand
– name: Auckland
PublicationTitle Drugs (New York, N.Y.)
PublicationTitleAbbrev Drugs
PublicationTitleAlternate Drugs
PublicationYear 2020
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Stets, Popescu, Gonong, Mitha, Nseir, Madej (CR90) 2019; 380
Kaushik, Ammerman, Martins, Parrish, Nuermberger (CR56) 2019; 63
Rodvold, Pai (CR93) 2019; 69
Heidrich, Mitova, Schedlbauer, Connell, Fucini, Steenbergen (CR8) 2016; 5
Karlowsky, Steenbergen, Zhanel (CR16) 2019; 69
Watkins, Deresinski (CR15) 2019; 69
Markley, Fang, Gasparrini, Symister, Kumar, Tolia (CR6) 2019; 5
Honeyman, Ismail, Nelson, Bhatia, Bowser, Chen (CR10) 2015; 59
Overcash, Bhiwandi, Garrity-Ryan, Steenbergen, Bai, Chitra (CR73) 2019; 63
CR34
Townsend, Pound, Drew (CR67) 2006; 60
Kaplan (CR69) 2011; 34
CR31
Dougherty, Sucher, Chahine, Shihadeh (CR21) 2019; 53
Roberts (CR22) 2005; 245
Chopra, Roberts (CR9) 2001; 65
Sun, Ting, Machineni, Praestgaard, Kuemmell, Stein (CR70) 2016; 60
Bax, de Vogel, Mouton, de Steenwinkel (CR58) 2019; 74
CR48
Berg, Tzanis, Garrity-Ryan, Bai, Chitra, Manley (CR75) 2018; 62
Abrahamian, Sakoulas, Tzanis, Manley, Steenbergen, Das (CR85) 2019; 69
Thaker, Spanogiannopoulos, Wright (CR2) 2010; 67
Pfaller, Rhomberg, Huband, Flamm (CR28) 2017; 61
Lindsay Grayson (CR52) 2017
Opal, File, van der Poll, Tzanis, Chitra, McGovern (CR92) 2019; 69
Heaney, Mahoney, Gallagher (CR42) 2019; 53
Macone, Caruso, Leahy, Donatelli, Weir, Draper (CR11) 2014; 58
CR50
Chen, Smith, Whitfield, Zucchi, Lasco, Bias (CR54) 2017; 88
Bassetti, Righi (CR57) 2014; 23
Nelson, Levy (CR18) 2011
Tanaka, Steenbergen, Villano (CR5) 2016; 24
Noel, Draper, Hait, Tanaka, Arbeit (CR87) 2012; 56
Lee, Kim, Hee Seo, Yong, Hoon Jeong, Lee (CR38) 2017; 87
Lepak, Zhao, Marchillo, VanHecker, Andes (CR82) 2019; 63
Gotfried, Horn, Garrity-Ryan, Villano, Tzanis, Chitra (CR76) 2017; 61
CR63
CR62
CR61
CR60
Nguyen, Starosta, Arenz, Sohmen, Dönhöfer, Wilson (CR20) 2014; 395
Pfaller, Huband, Streit, Flamm, Sader (CR30) 2018; 51
O’Riordan, Cardenas, Shin, Sirbu, Garrity-Ryan, Das (CR89) 2019; 19
Welsh, Gaydos, Quinn (CR43) 1996; 40
Lin, Flarakos, Du, Hu, He, Mangold (CR78) 2017; 61
Carvalhaes, Huband, Reinhart, Flamm, Sader (CR65) 2019; 63
Ramirez, Tzanis, Curran, Noble, Chitra, Manley (CR91) 2019; 69
Luna, King, Gulledge, Cannons, Amuso, Cattani (CR41) 2007; 60
Bundrant, Tzanis, Garrity-Ryan, Bai, Chitra, Manley (CR72) 2018; 62
CR79
CR74
Zhanel, Siemens, Slayter, Mandell (CR101) 1999; 10
Zhanel, Homenuik, Nichol, Noreddin, Vercaigne, Embil (CR3) 2004; 64
Zhanel, Cheung, Adam, Zelenitsky, Golden, Schweizer (CR12) 2016; 76
Felmingham (CR40) 2005; 17
Sader, Mendes, Le, Denys, Flamm, Jones (CR33) 2019; 6
Huband, Pfaller, Shortridge, Flamm (CR17) 2019; 19
Flarakos, Du, Gu, Wang, Einolf, Chun (CR77) 2017; 47
Goldstein, Citron, Tyrrell, Leoncio, Merriama (CR46) 2018; 62
Shoen, Benaroch, Sklaney, Cynamon, Benaroch, Cynamon (CR45) 2019; 63
CR86
Gallagher (CR14) 2019; 69
CR84
Waites, Crabb, Liu, Duffy (CR49) 2016; 60
CR81
CR80
Stapert, Wolfe, Shinabarger, Marra, Pillar (CR44) 2018; 62
Tzanis, Manley, Villano, Tanaka, Bai, Loh (CR71) 2017; 57
Fluit, van Gorkum, Vlooswijk (CR64) 2019; 94
Jamal, Rotimi, Pal, Sonnevend, Dimitrov (CR55) 2010; 3
Pfaller, Rhomberg, Huband, Flamm (CR68) 2018; 91
CR13
CR99
CR98
Bopp, Baltch, Ritz, Michelsen, Smith (CR36) 2011; 69
CR97
CR96
CR95
CR94
Pfaller, Rhomberg, Huband, Flamm (CR27) 2018; 90
Steenbergen, Tanaka, Miller, Halasohoris, Hershfield (CR47) 2017; 61
O’Riordan, Green, Overcash, Puljiz, Metallidis, Gardovskis (CR88) 2019; 380
Durães (CR23) 2019; 12
Bishburg, Bishburg (CR53) 2009; 34
Zhanel, Karlowsky, Rubinstein, Hoban (CR19) 2006; 4
Marshall, Levy (CR7) 2011; 24
Noskin (CR35) 2005; 41
Pfaller, Huband, Rhomberg, Flamm (CR29) 2017; 61
Sutcliffe (CR59) 2011; 1241
CR26
Betriu, Culebras, Gómez, Rodríguez-Avial, Picazo (CR39) 2005; 56
CR24
Cunha, Sibley, Ristuccia (CR51) 1982; 4
Draper, Weir, Macone, Donatelli, Trieber, Tanaka (CR4) 2014; 58
Farrell, Turnidge, Bell, Sader, Jones (CR32) 2010; 60
Lepak, Zhao, Marchillo, VanHecker, Andes (CR83) 2017; 61
CR100
Pfaller, Huband, Shortridge, Flamm (CR66) 2018; 62
Nelson, Levy (CR1) 2011; 1241
Villano, Steenbergen, Loh (CR25) 2016; 11
McKeage, Keating (CR37) 2008; 68
M Heaney (1257_CR42) 2019; 53
1257_CR80
MA Pfaller (1257_CR66) 2018; 62
1257_CR84
MP Draper (1257_CR4) 2014; 58
DJ Farrell (1257_CR32) 2010; 60
1257_CR100
JA Ramirez (1257_CR91) 2019; 69
1257_CR81
1257_CR86
I Chopra (1257_CR9) 2001; 65
L Welsh (1257_CR43) 1996; 40
MH Gotfried (1257_CR76) 2017; 61
HS Sader (1257_CR33) 2019; 6
SK Tanaka (1257_CR5) 2016; 24
JA Dougherty (1257_CR21) 2019; 53
1257_CR74
1257_CR79
A Chen (1257_CR54) 2017; 88
JA Sutcliffe (1257_CR59) 2011; 1241
JS Overcash (1257_CR73) 2019; 63
MA Pfaller (1257_CR30) 2018; 51
FM Abrahamian (1257_CR85) 2019; 69
J Flarakos (1257_CR77) 2017; 47
JK Berg (1257_CR75) 2018; 62
AJ Lepak (1257_CR83) 2017; 61
W Lin (1257_CR78) 2017; 61
1257_CR62
H Sun (1257_CR70) 2016; 60
1257_CR61
1257_CR60
L Stapert (1257_CR44) 2018; 62
EJC Goldstein (1257_CR46) 2018; 62
1257_CR63
ML Nelson (1257_CR18) 2011
C Betriu (1257_CR39) 2005; 56
JA Karlowsky (1257_CR16) 2019; 69
MA Pfaller (1257_CR68) 2018; 91
D Felmingham (1257_CR40) 2005; 17
AB Macone (1257_CR11) 2014; 58
GJ Noel (1257_CR87) 2012; 56
1257_CR50
A Kaushik (1257_CR56) 2019; 63
W O’Riordan (1257_CR88) 2019; 380
JL Markley (1257_CR6) 2019; 5
Sousa Durães (1257_CR23) 2019; 12
VA Luna (1257_CR41) 2007; 60
LH Bopp (1257_CR36) 2011; 69
GG Zhanel (1257_CR3) 2004; 64
GA Noskin (1257_CR35) 2005; 41
AC Fluit (1257_CR64) 2019; 94
HI Bax (1257_CR58) 2019; 74
ML Nelson (1257_CR1) 2011; 1241
MA Pfaller (1257_CR27) 2018; 90
F Nguyen (1257_CR20) 2014; 395
1257_CR48
M Bassetti (1257_CR57) 2014; 23
CG Carvalhaes (1257_CR65) 2019; 63
M Lindsay Grayson (1257_CR52) 2017
MA Pfaller (1257_CR28) 2017; 61
J Steenbergen (1257_CR47) 2017; 61
W O’Riordan (1257_CR89) 2019; 19
K McKeage (1257_CR37) 2008; 68
GG Zhanel (1257_CR12) 2016; 76
H Lee (1257_CR38) 2017; 87
1257_CR31
MD Huband (1257_CR17) 2019; 19
W Jamal (1257_CR55) 2010; 3
BM Marshall (1257_CR7) 2011; 24
MC Roberts (1257_CR22) 2005; 245
1257_CR34
KB Waites (1257_CR49) 2016; 60
GG Zhanel (1257_CR19) 2006; 4
GG Zhanel (1257_CR101) 1999; 10
R Stets (1257_CR90) 2019; 380
JB Kaplan (1257_CR69) 2011; 34
JC Gallagher (1257_CR14) 2019; 69
1257_CR26
LA Bundrant (1257_CR72) 2018; 62
L Honeyman (1257_CR10) 2015; 59
1257_CR24
AJ Lepak (1257_CR82) 2019; 63
C Heidrich (1257_CR8) 2016; 5
S Villano (1257_CR25) 2016; 11
C Shoen (1257_CR45) 2019; 63
M Thaker (1257_CR2) 2010; 67
BA Cunha (1257_CR51) 1982; 4
RR Watkins (1257_CR15) 2019; 69
KA Rodvold (1257_CR93) 2019; 69
E Tzanis (1257_CR71) 2017; 57
1257_CR95
1257_CR94
S Opal (1257_CR92) 2019; 69
E Bishburg (1257_CR53) 2009; 34
1257_CR99
MA Pfaller (1257_CR29) 2017; 61
1257_CR98
1257_CR97
1257_CR96
ML Townsend (1257_CR67) 2006; 60
1257_CR13
References_xml – volume: 53
  start-page: 486
  year: 2019
  end-page: 500
  ident: CR21
  article-title: Omadacycline: a new tetracycline antibiotic
  publication-title: Ann Pharmacother
– ident: CR97
– ident: CR74
– volume: 380
  start-page: 517
  year: 2019
  end-page: 527
  ident: CR90
  article-title: Omadacycline for community-acquired bacterial pneumonia
  publication-title: N Engl J Med
– volume: 23
  start-page: 1575
  year: 2014
  end-page: 1584
  ident: CR57
  article-title: Eravacycline for the treatment of intra-abdominal infections
  publication-title: Expert Opin Investig Drugs
– volume: 56
  start-page: 5650
  year: 2012
  end-page: 5654
  ident: CR87
  article-title: A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections
  publication-title: Antimicrob Agents Chemother
– ident: CR80
– volume: 41
  start-page: S303
  year: 2005
  end-page: S314
  ident: CR35
  article-title: Tigecycline: a new glycylcycline for treatment of serious infections
  publication-title: Clin Infect Dis
– volume: 61
  start-page: e01135–17
  year: 2017
  ident: CR76
  article-title: Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects
  publication-title: Antimicrob Agents Chemother
– volume: 380
  start-page: 528
  year: 2019
  end-page: 538
  ident: CR88
  article-title: Omadacycline for acute bacterial skin and skin-structure infections
  publication-title: N Engl J Med
– volume: 61
  start-page: e01784–16
  year: 2017
  ident: CR78
  article-title: Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of C-omadacycline in rats
  publication-title: Antimicrob Agents Chemother
– volume: 64
  start-page: 63
  year: 2004
  end-page: 88
  ident: CR3
  article-title: The glycylcyclines
  publication-title: Drugs
– volume: 17
  start-page: 5
  year: 2005
  end-page: 11
  ident: CR40
  article-title: Tigecycline—the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline
  publication-title: J Chemother
– volume: 69
  start-page: S23
  year: 2019
  end-page: S32
  ident: CR85
  article-title: Omadacycline for acute bacterial skin and skin structure infections
  publication-title: Clin Infect Dis
– volume: 87
  start-page: 160
  year: 2017
  end-page: 162
  ident: CR38
  article-title: In vitro activity of tigecycline alone and antimicrobial combinations against clinical isolates
  publication-title: Diagn Microbiol Infect Dis
– ident: CR60
– volume: 24
  start-page: 718
  year: 2011
  end-page: 733
  ident: CR7
  article-title: Food animals and antimicrobials: impacts on human health
  publication-title: Clin Microbiol Rev
– volume: 61
  start-page: e02434–16
  year: 2017
  ident: CR47
  article-title: and activity of omadacycline against two biothreat pathogens, and
  publication-title: Antimicrob Agents Chemother
– volume: 34
  start-page: 737
  year: 2011
  end-page: 751
  ident: CR69
  article-title: Antibiotic-induced biofilm formation
  publication-title: Int J Artif Organs
– volume: 63
  start-page: e02262–18
  year: 2019
  ident: CR65
  article-title: Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)
  publication-title: Antimicrob Agents Chemother
– volume: 3
  start-page: 35
  year: 2010
  end-page: 42
  ident: CR55
  article-title: Comparative activity of tigecycline and other antimicrobial agents against species from Kuwait and the United Arab of Emirates
  publication-title: J Infect Public Health
– ident: CR100
– volume: 24
  start-page: 6409
  year: 2016
  end-page: 6419
  ident: CR5
  article-title: Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic
  publication-title: Bioorg Med Chem
– volume: 90
  start-page: 143
  year: 2018
  end-page: 147
  ident: CR27
  article-title: Activity of omadacycline tested against from a global surveillance program (2014)
  publication-title: Diagn Microbiol Infect Dis
– volume: 60
  start-page: 1662
  year: 2006
  end-page: 1672
  ident: CR67
  article-title: Tigecycline: a new glycylcycline antimicrobial
  publication-title: Int J Clin Pract
– volume: 69
  start-page: S6
  year: 2019
  end-page: S15
  ident: CR16
  article-title: Microbiology and preclinical review of omadacycline
  publication-title: Clin Infect Dis
– ident: CR86
– volume: 63
  start-page: e00624–19
  year: 2019
  ident: CR82
  article-title: pharmacodynamics of omadacycline against in the neutropenic murine thigh infection model
  publication-title: Antimicrob Agents Chemother
– ident: CR63
– volume: 10
  start-page: 429
  year: 1999
  end-page: 433
  ident: CR101
  article-title: Antibiotic and oral contraceptive drug interactions: is there a need for concern?
  publication-title: Can J Infect Dis
– volume: 69
  start-page: 890
  year: 2019
  end-page: 896
  ident: CR15
  article-title: Omadacycline: a novel tetracycline derivative with oral and intravenous formulations
  publication-title: Clin Infect Dis
– volume: 5
  start-page: 618
  year: 2019
  end-page: 633
  ident: CR6
  article-title: Semisynthetic analogues of anhydrotetracycline as inhibitors of tetracycline destructase enzymes
  publication-title: ACS Infect Dis
– ident: CR94
– volume: 40
  start-page: 212
  year: 1996
  end-page: 214
  ident: CR43
  article-title: In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of
  publication-title: Antimicrob Agents Chemother
– volume: 62
  start-page: e01487–17
  year: 2018
  ident: CR72
  article-title: Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens
  publication-title: Antimicrob Agents Chemother
– ident: CR13
– volume: 1241
  start-page: 122
  year: 2011
  end-page: 152
  ident: CR59
  article-title: Antibiotics in development targeting protein synthesis
  publication-title: Ann N Y Acad Sci
– volume: 91
  start-page: 179
  year: 2018
  end-page: 183
  ident: CR68
  article-title: Activity of omadacycline tested against causing urinary tract infections from a global surveillance program (2014)
  publication-title: Diagn Microbiol Infect Dis
– ident: CR24
– volume: 57
  start-page: 321
  year: 2017
  end-page: 327
  ident: CR71
  article-title: Effect of food on the bioavailability of omadacycline in healthy participants
  publication-title: J Clin Pharmacol
– volume: 62
  start-page: e00047–18
  year: 2018
  ident: CR44
  article-title: In vitro activities of omadacycline and comparators against anaerobic bacteria
  publication-title: Antimicrob Agents Chemother
– volume: 61
  start-page: e00018–17
  year: 2017
  ident: CR29
  article-title: Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010–2011
  publication-title: Antimicrob Agents Chemother
– volume: 63
  start-page: e00470–19
  year: 2019
  ident: CR56
  article-title: activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of
  publication-title: Antimicrob Agents Chemother
– volume: 1241
  start-page: 17
  year: 2011
  end-page: 32
  ident: CR1
  article-title: The history of the tetracyclines
  publication-title: Ann N Y Acad Sci
– volume: 68
  start-page: 2633
  year: 2008
  end-page: 2644
  ident: CR37
  article-title: Tigecycline: in community-acquired pneumonia
  publication-title: Drugs
– volume: 63
  start-page: e02083–18
  year: 2019
  ident: CR73
  article-title: Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a phase 1 study
  publication-title: Antimicrob Agents Chemother
– volume: 61
  start-page: e02368–16
  year: 2017
  ident: CR83
  article-title: pharmacodynamic evaluation of omadacycline (PTK 0796) against in the murine pneumonia model
  publication-title: Antimicrob Agents Chemother
– volume: 56
  start-page: 349
  year: 2005
  end-page: 352
  ident: CR39
  article-title: activity of tigecycline against species
  publication-title: J Antimicrob Chemother
– start-page: 1230
  year: 2017
  end-page: 1248
  ident: CR52
  publication-title: Minocycline Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs
– ident: CR61
– volume: 69
  start-page: S33
  year: 2019
  end-page: S39
  ident: CR91
  article-title: Early clinical response in community-acquired bacterial pneumonia: from clinical endpoint to clinical practice
  publication-title: Clin Infect Dis
– volume: 4
  start-page: 9
  year: 2006
  end-page: 25
  ident: CR19
  article-title: Tigecycline: a novel glycylcycline antibiotic
  publication-title: Expert Rev Anti Infect Ther
– volume: 60
  start-page: 555
  year: 2007
  end-page: 567
  ident: CR41
  article-title: Susceptibility of , and to 24 antimicrobials using Sensititre(R) automated microbroth dilution and Etest(R) agar gradient diffusion methods
  publication-title: J Antimicrob Chemother
– volume: 12
  start-page: 63
  year: 2019
  ident: CR23
  article-title: Omadacycline: a newly approved antibacterial from the class of tetracyclines
  publication-title: Pharmaceuticals
– volume: 395
  start-page: 559
  year: 2014
  end-page: 575
  ident: CR20
  article-title: Tetracycline antibiotics and resistance mechanisms
  publication-title: Biol Chem
– volume: 94
  start-page: 78
  year: 2019
  end-page: 80
  ident: CR64
  article-title: Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants
  publication-title: Diagn Microbiol Infect Dis
– ident: CR84
– volume: 65
  start-page: 232
  year: 2001
  end-page: 260
  ident: CR9
  article-title: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance
  publication-title: Microbiol Mol Biol Rev
– volume: 88
  start-page: 365
  year: 2017
  end-page: 367
  ident: CR54
  article-title: Activity of minocycline against (KPC)-producing E clinical isolates, with comparison to doxycycline and tigecycline
  publication-title: Diagn Microbiol Infect Dis
– ident: CR96
– start-page: 269
  year: 2011
  end-page: 283
  ident: CR18
  publication-title: Tetracyclines and tetracycline derivatives. Comprehensive Biotechnology
– ident: CR50
– volume: 245
  start-page: 195
  year: 2005
  end-page: 203
  ident: CR22
  article-title: Update on acquired tetracycline resistance genes
  publication-title: FEMS Microbiol Lett
– volume: 60
  start-page: 440
  year: 2010
  end-page: 451
  ident: CR32
  article-title: The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008)
  publication-title: J Infect
– volume: 47
  start-page: 682
  year: 2017
  end-page: 696
  ident: CR77
  article-title: Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline
  publication-title: Xenobiotica
– volume: 58
  start-page: 1127
  year: 2014
  end-page: 1135
  ident: CR11
  article-title: In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline
  publication-title: Antimicrob Agents Chemother
– volume: 63
  start-page: e02522–18
  year: 2019
  ident: CR45
  article-title: In vitro activities of omadacycline against rapidly growing mycobacteria
  publication-title: Antimicrob Agents Chemother
– volume: 53
  start-page: 1124
  year: 2019
  end-page: 1135
  ident: CR42
  article-title: Eravacycline: the tetracyclines strike back
  publication-title: Ann Pharmacother
– volume: 59
  start-page: 7044
  year: 2015
  end-page: 7053
  ident: CR10
  article-title: Structure–activity relationship of the aminomethylcyclines and the discovery of omadacycline
  publication-title: Antimicrob Agents Chemother
– volume: 34
  start-page: 395
  year: 2009
  end-page: 401
  ident: CR53
  article-title: Minocycline—an old drug for a new century: emphasis on (MRSA) and i
  publication-title: Int J Antimicrob Agents
– ident: CR81
– ident: CR26
– ident: CR99
– volume: 67
  start-page: 419
  year: 2010
  end-page: 431
  ident: CR2
  article-title: The tetracycline resistome
  publication-title: Cell Mol Life Sci
– ident: CR95
– volume: 19
  start-page: 56
  year: 2019
  end-page: 63
  ident: CR17
  article-title: Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY antimicrobial surveillance programme, 2017
  publication-title: J Glob Antimicrob Resist
– volume: 11
  start-page: 1421
  year: 2016
  end-page: 1434
  ident: CR25
  article-title: Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections
  publication-title: Future Microbiol
– volume: 69
  start-page: S1
  year: 2019
  end-page: S5
  ident: CR14
  article-title: Omadacycline: a modernized tetracycline
  publication-title: Clin Infect Dis
– volume: 58
  start-page: 1279
  year: 2014
  end-page: 1283
  ident: CR4
  article-title: Mechanism of action of the novel aminomethylcycline antibiotic omadacycline
  publication-title: Antimicrob Agents Chemother
– ident: CR79
– ident: CR98
– volume: 69
  start-page: 86
  year: 2011
  end-page: 93
  ident: CR36
  article-title: Activities of tigecycline and comparators against and extracellularly and in human monocyte-derived macrophages
  publication-title: Diagn Microbiol Infect Dis
– volume: 4
  start-page: 115
  year: 1982
  end-page: 135
  ident: CR51
  article-title: Doxyxycline
  publication-title: Ther Drug Monit
– volume: 19
  start-page: 1080
  issue: 10
  year: 2019
  end-page: 1090
  ident: CR89
  article-title: Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial
  publication-title: Lancet Infect Dis
– volume: 74
  start-page: 2930
  year: 2019
  end-page: 2933
  ident: CR58
  article-title: Omadacycline as a promising new agent for the treatment of infections with
  publication-title: J Antimicrob Chemother
– volume: 69
  start-page: S40
  year: 2019
  end-page: S47
  ident: CR92
  article-title: An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic
  publication-title: Clin Infect Dis
– ident: CR48
– volume: 51
  start-page: 848
  year: 2018
  end-page: 853
  ident: CR30
  article-title: Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)
  publication-title: Int J Antimicrob Agents
– ident: CR31
– volume: 76
  start-page: 567
  year: 2016
  end-page: 588
  ident: CR12
  article-title: Review of eravacycline, a novel fluorocycline antibacterial agent
  publication-title: Drugs
– volume: 62
  start-page: e02551–17
  year: 2018
  ident: CR46
  article-title: Comparative in vitro activity of omadacycline against dog and cat bite wound isolates
  publication-title: Antimicrob Agents Chemother
– volume: 5
  start-page: 32
  year: 2016
  ident: CR8
  article-title: The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome
  publication-title: Antibiotics
– volume: 61
  start-page: e02411–16
  year: 2017
  ident: CR28
  article-title: Activities of omadacycline and comparator agents against isolates from a surveillance program conducted in North America and Europe
  publication-title: Antimicrob Agents Chemother
– volume: 60
  start-page: 7431
  year: 2016
  end-page: 7435
  ident: CR70
  article-title: Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects
  publication-title: Antimicrob Agents Chemother
– ident: CR34
– volume: 69
  start-page: S16
  year: 2019
  end-page: S22
  ident: CR93
  article-title: Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline
  publication-title: Clin Infect Dis
– volume: 62
  start-page: e02057–17
  year: 2018
  ident: CR75
  article-title: Pharmacokinetics and safety of omadacycline in subjects with impaired renal function
  publication-title: Antimicrob Agents Chemother
– volume: 60
  start-page: 7502
  year: 2016
  end-page: 7504
  ident: CR49
  article-title: In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human and
  publication-title: Antimicrob Agents Chemother
– volume: 6
  start-page: S14
  year: 2019
  end-page: S23
  ident: CR33
  article-title: Antimicrobial susceptibility of for North America, Europe, Latin America, and the Asia-Pasific Region: results from 20 years of the SENTRY antimicrobial surveillance program (1997–2016)
  publication-title: Open Forum Infect Dis
– ident: CR62
– volume: 62
  start-page: e02327–17
  year: 2018
  ident: CR66
  article-title: Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as PART of the 2016 SENTRY antimicrobial surveillance program
  publication-title: Antimicrob Agents Chemother
– volume: 69
  start-page: 86
  year: 2011
  ident: 1257_CR36
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2010.08.023
– volume: 60
  start-page: 7502
  year: 2016
  ident: 1257_CR49
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01734-16
– volume: 24
  start-page: 6409
  year: 2016
  ident: 1257_CR5
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2016.07.029
– ident: 1257_CR81
– volume: 61
  start-page: e00018–17
  year: 2017
  ident: 1257_CR29
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00018-17
– volume: 4
  start-page: 115
  year: 1982
  ident: 1257_CR51
  publication-title: Ther Drug Monit
  doi: 10.1097/00007691-198206000-00001
– volume: 59
  start-page: 7044
  year: 2015
  ident: 1257_CR10
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01536-15
– volume: 62
  start-page: e02057–17
  year: 2018
  ident: 1257_CR75
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02057-17
– volume: 63
  start-page: e00624–19
  year: 2019
  ident: 1257_CR82
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00624-19
– volume: 56
  start-page: 349
  year: 2005
  ident: 1257_CR39
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dki197
– ident: 1257_CR95
– volume: 61
  start-page: e02411–16
  year: 2017
  ident: 1257_CR28
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02411-16
– ident: 1257_CR63
– volume: 63
  start-page: e02083–18
  year: 2019
  ident: 1257_CR73
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02083-18
– volume: 88
  start-page: 365
  year: 2017
  ident: 1257_CR54
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2017.05.004
– volume: 10
  start-page: 429
  year: 1999
  ident: 1257_CR101
  publication-title: Can J Infect Dis
– ident: 1257_CR84
– volume: 62
  start-page: e00047–18
  year: 2018
  ident: 1257_CR44
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00047-18
– volume: 60
  start-page: 1662
  year: 2006
  ident: 1257_CR67
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2006.01188.x
– ident: 1257_CR31
– ident: 1257_CR61
  doi: 10.26226/morressier.56d6be7ad462b80296c97dee
– volume: 67
  start-page: 419
  year: 2010
  ident: 1257_CR2
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-009-0172-6
– volume: 61
  start-page: e02368–16
  year: 2017
  ident: 1257_CR83
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02368-16
– volume: 63
  start-page: e02262–18
  year: 2019
  ident: 1257_CR65
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02262-18
– volume: 60
  start-page: 440
  year: 2010
  ident: 1257_CR32
  publication-title: J Infect
  doi: 10.1016/j.jinf.2010.03.024
– ident: 1257_CR98
– volume: 61
  start-page: e02434–16
  year: 2017
  ident: 1257_CR47
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02434-16
– volume: 5
  start-page: 618
  year: 2019
  ident: 1257_CR6
  publication-title: ACS Infect Dis
  doi: 10.1021/acsinfecdis.8b00349
– volume: 60
  start-page: 555
  year: 2007
  ident: 1257_CR41
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkm213
– volume: 90
  start-page: 143
  year: 2018
  ident: 1257_CR27
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2017.10.010
– volume: 51
  start-page: 848
  year: 2018
  ident: 1257_CR30
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2018.01.006
– volume: 56
  start-page: 5650
  year: 2012
  ident: 1257_CR87
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00948-12
– volume: 69
  start-page: S40
  year: 2019
  ident: 1257_CR92
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz398
– volume: 61
  start-page: e01135–17
  year: 2017
  ident: 1257_CR76
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01135-17
– volume: 1241
  start-page: 17
  year: 2011
  ident: 1257_CR1
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.2011.06354.x
– volume: 62
  start-page: e02327–17
  year: 2018
  ident: 1257_CR66
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02327-17
– ident: 1257_CR60
– ident: 1257_CR26
– ident: 1257_CR34
  doi: 10.1128/AAC.01135-17
– ident: 1257_CR74
– volume: 12
  start-page: 63
  year: 2019
  ident: 1257_CR23
  publication-title: Pharmaceuticals
  doi: 10.3390/ph12020063
– volume: 62
  start-page: e02551–17
  year: 2018
  ident: 1257_CR46
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02551-17
– volume: 94
  start-page: 78
  year: 2019
  ident: 1257_CR64
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2018.11.010
– volume: 4
  start-page: 9
  year: 2006
  ident: 1257_CR19
  publication-title: Expert Rev Anti Infect Ther
  doi: 10.1586/14787210.4.1.9
– volume: 69
  start-page: 890
  year: 2019
  ident: 1257_CR15
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz242
– volume: 24
  start-page: 718
  year: 2011
  ident: 1257_CR7
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.00002-11
– volume: 69
  start-page: S6
  year: 2019
  ident: 1257_CR16
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz395
– volume: 40
  start-page: 212
  year: 1996
  ident: 1257_CR43
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.40.1.212
– volume: 6
  start-page: S14
  year: 2019
  ident: 1257_CR33
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofy263
– start-page: 269
  volume-title: Tetracyclines and tetracycline derivatives. Comprehensive Biotechnology
  year: 2011
  ident: 1257_CR18
– volume: 245
  start-page: 195
  year: 2005
  ident: 1257_CR22
  publication-title: FEMS Microbiol Lett
  doi: 10.1016/j.femsle.2005.02.034
– ident: 1257_CR48
– ident: 1257_CR100
– ident: 1257_CR62
  doi: 10.26226/morressier.56d6be7ad462b80296c97ddc
– ident: 1257_CR79
– ident: 1257_CR24
  doi: 10.1093/ofid/ofy210.1208
– volume: 19
  start-page: 56
  year: 2019
  ident: 1257_CR17
  publication-title: J Glob Antimicrob Resist
  doi: 10.1016/j.jgar.2019.02.017
– volume: 74
  start-page: 2930
  year: 2019
  ident: 1257_CR58
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkz267
– volume: 60
  start-page: 7431
  year: 2016
  ident: 1257_CR70
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01393-16
– volume: 1241
  start-page: 122
  year: 2011
  ident: 1257_CR59
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.2011.06323.x
– ident: 1257_CR96
– volume: 17
  start-page: 5
  year: 2005
  ident: 1257_CR40
  publication-title: J Chemother
  doi: 10.1179/joc.2005.17.Supplement-1.5
– volume: 57
  start-page: 321
  year: 2017
  ident: 1257_CR71
  publication-title: J Clin Pharmacol
  doi: 10.1002/jcph.814
– volume: 76
  start-page: 567
  year: 2016
  ident: 1257_CR12
  publication-title: Drugs
  doi: 10.1007/s40265-016-0545-8
– volume: 53
  start-page: 1124
  year: 2019
  ident: 1257_CR42
  publication-title: Ann Pharmacother
  doi: 10.1177/1060028019850173
– volume: 64
  start-page: 63
  year: 2004
  ident: 1257_CR3
  publication-title: Drugs
  doi: 10.2165/00003495-200464010-00005
– volume: 91
  start-page: 179
  year: 2018
  ident: 1257_CR68
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2018.01.019
– volume: 68
  start-page: 2633
  year: 2008
  ident: 1257_CR37
  publication-title: Drugs
  doi: 10.2165/0003495-200868180-00008
– volume: 5
  start-page: 32
  year: 2016
  ident: 1257_CR8
  publication-title: Antibiotics
  doi: 10.3390/antibiotics5040032
– volume: 47
  start-page: 682
  year: 2017
  ident: 1257_CR77
  publication-title: Xenobiotica
  doi: 10.1080/00498254.2016.1213465
– ident: 1257_CR99
– volume: 380
  start-page: 528
  year: 2019
  ident: 1257_CR88
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1800170
– volume: 69
  start-page: S33
  year: 2019
  ident: 1257_CR91
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz397
– volume: 11
  start-page: 1421
  year: 2016
  ident: 1257_CR25
  publication-title: Future Microbiol
  doi: 10.2217/fmb-2016-0100
– volume: 69
  start-page: S1
  year: 2019
  ident: 1257_CR14
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz394
– volume: 53
  start-page: 486
  year: 2019
  ident: 1257_CR21
  publication-title: Ann Pharmacother
  doi: 10.1177/1060028018818094
– volume: 23
  start-page: 1575
  year: 2014
  ident: 1257_CR57
  publication-title: Expert Opin Investig Drugs
  doi: 10.1517/13543784.2014.965253
– ident: 1257_CR80
– volume: 69
  start-page: S16
  year: 2019
  ident: 1257_CR93
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz309
– volume: 34
  start-page: 395
  year: 2009
  ident: 1257_CR53
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2009.06.021
– volume: 61
  start-page: e01784–16
  year: 2017
  ident: 1257_CR78
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01784-16
– volume: 87
  start-page: 160
  year: 2017
  ident: 1257_CR38
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2016.10.022
– volume: 65
  start-page: 232
  year: 2001
  ident: 1257_CR9
  publication-title: Microbiol Mol Biol Rev
  doi: 10.1128/MMBR.65.2.232-260.2001
– ident: 1257_CR94
– volume: 69
  start-page: S23
  year: 2019
  ident: 1257_CR85
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz396
– volume: 58
  start-page: 1127
  year: 2014
  ident: 1257_CR11
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01242-13
– ident: 1257_CR97
– start-page: 1230
  volume-title: Minocycline Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs
  year: 2017
  ident: 1257_CR52
  doi: 10.1201/9781498747967
– volume: 395
  start-page: 559
  year: 2014
  ident: 1257_CR20
  publication-title: Biol Chem
  doi: 10.1515/hsz-2013-0292
– volume: 58
  start-page: 1279
  year: 2014
  ident: 1257_CR4
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01066-13
– volume: 34
  start-page: 737
  year: 2011
  ident: 1257_CR69
  publication-title: Int J Artif Organs
  doi: 10.5301/ijao.5000027
– volume: 19
  start-page: 1080
  issue: 10
  year: 2019
  ident: 1257_CR89
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(19)30275-0
– ident: 1257_CR13
– ident: 1257_CR86
– volume: 63
  start-page: e02522–18
  year: 2019
  ident: 1257_CR45
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02522-18
– volume: 380
  start-page: 517
  year: 2019
  ident: 1257_CR90
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1800201
– volume: 41
  start-page: S303
  year: 2005
  ident: 1257_CR35
  publication-title: Clin Infect Dis
  doi: 10.1086/431672
– volume: 63
  start-page: e00470–19
  year: 2019
  ident: 1257_CR56
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00470-19
– ident: 1257_CR50
– volume: 62
  start-page: e01487–17
  year: 2018
  ident: 1257_CR72
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01487-17
– volume: 3
  start-page: 35
  year: 2010
  ident: 1257_CR55
  publication-title: J Infect Public Health
  doi: 10.1016/j.jiph.2009.10.001
SSID ssj0012959
Score 2.5713315
SecondaryResourceType review_article
Snippet Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 285
SubjectTerms Administration, Intravenous
Administration, Oral
Animal models
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacology
Antibacterial activity
Antibiotic resistance
Antibiotics
Bacteria
Binding
Bioavailability
Bronchopulmonary infection
Clinical trials
Community-Acquired Infections - drug therapy
Comparators
Cystitis
Drug resistance
Efflux
FDA approval
Gram-Negative Bacteria - drug effects
Gram-Positive Bacteria - drug effects
Humans
Internal Medicine
Intravenous administration
Intravenous infusion
Linezolid
Medicine
Medicine & Public Health
Methicillin
Minimum inhibitory concentration
Minocycline
Moxifloxacin
Neutropenia
Oral administration
Organic chemistry
Pathogens
Patients
Pharmacodynamics
Pharmacokinetics
Pharmacology
Pharmacology/Toxicology
Pharmacotherapy
Pneumonia
Protein biosynthesis
Protein synthesis
Proteins
Pyelonephritis
Review Article
Rings (mathematics)
Side effects
Skin
Skin Diseases, Bacterial - drug therapy
Staphylococcus aureus
Staphylococcus infections
Streptococcus infections
Tetracyclines
Tetracyclines - administration & dosage
Tetracyclines - pharmacology
Therapy
Thigh
Tigecycline
Title Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent
URI https://link.springer.com/article/10.1007/s40265-020-01257-4
https://www.ncbi.nlm.nih.gov/pubmed/31970713
https://www.proquest.com/docview/2362908148
https://www.proquest.com/docview/2344229109
Volume 80
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7a5NJL6bvbpEGFkktX1JZka9VL8ZYsaaHOUhLYm5ElBQobO81uAvvvO2NrvZTQnHywLIvRPD495huAj4k2XhLzY-ad5SpNLjnFGZ5YFxDep0E42hr4WeanF-rHIlvEDbdVvFa59Ymdo_atoz3yzwI9rcH4pSZfr_9wqhpFp6uxhMZj2CfqMtJqvRgWXBjKsh7-poIjTNcxaaZLncN1U065yXQtC9WWq38D0z20ee-ktAtAs2fwNCJHVvRT_RweheYFHM976unNmJ3vMqlWY3bM5jtS6s1LKM-urMd2lAkZvrCCle1dWLKzG-zSNp59p03eu46wlRVXv5uWSktvlvEDVjSUW9Ji36ygZKxXcDE7Of92ymMtBe6kztbceqeFDEJYtDiXyty5kHpVZ7V2iQvaBKXqgOjKJMY7ab2xKa5WvK2l89Ip-Rr2mrYJb4HlRIETrEBTl0rZMNETWefu0hjrERyaEaRbQVYuEo1TvYtlNVAkd8KvUPhVJ_xKjeDT8M11T7PxYOvD7fxU0eRW1U5BRvBheI3GQicgtgkoP2yjlBCIkHCQb_p5HX6HvkjTkn0E4-1E7zr__1jePTyWA3giOiWjCzCHsLe-uQ3vEcas66NOV49gv5hNpyU-pyfl_NdfSV_ubg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9swED8x9rC9TPteGWyetPGyWktsJ6mRpinahtoBhYci9S04tpEmlQRoAfWf2t-4u3xVExpvPMe-WHfnu9_ZvjuAj0GinaTKj5GzhqswOOXkZ3hgrEd4H3ph6WjgYBwPj9WvaTRdgz9tLgw9q2xtYmWoXWnpjPyLQEur0X-pwbfzC05do-h2tW2hUavFnl_eYMg2_zr6gfL9JMTuz8n3IW-6CnArk2jBjbOJkF4Ig7pnQxlb60On8ihPbGB9or1SuUecoQPtrDROmxBxuzO5tE5aJZHuA3iIjjegYC-ZdgEeus6ohtuh4BgWJE2STpWqh3FaTLnQ9AwMtwlX_zrCW-j21s1s5fB2n8KTBqmytFatZ7Dmi-ewfVSXul722WSVuTXvs212tCqCvXwB48Mz43AcZV76HZaycXntZ-zwEkmawrERHSpfVwViWXr2uyiplfVy1kxgaUG5LCXSZiklf72E43vh8itYL8rCvwEWU8kdbwSaFqmU8YNkIPPYnmptHIJR3YOwZWRmm8Lm1F9jlnUlmSvmZ8j8rGJ-pnrwuZtzXpf1uHP0ZiufrNni82ylkD340H3GzUk3LqbwyD8co5QQiMhwka9ruXa_Q9uX0BFBD_qtoFfE_7-WjbvX8h4eDScH-9n-aLz3Fh6LSuHo8c0mrC8ur_wWQqhF_q7SWwYn971R_gIw8Cm2
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anYR4QYxrYYCRYC80WmI7SY00TYGtWhlkFdqkvWWO7UpIXTLWMtS_xq_bOblVaGJve47tWMfn8tnnBvDej5UVVPkxtEZ7MvCnHtkZz9fGIbwPHDf0NPA9jQ5O5NfT8HQN_ra5MBRW2erESlHb0tAb-TZHTavQfsnh9rQJi5jsjXYvfnnUQYo8rW07jZpFDt3yD17f5jvjPTzrD5yP9o-_HHhNhwHPiDhceNqamAvHuUY-NIGIjHGBlXmYx8Y3LlZOytwh5lC-skZoq3SAGN7qXBgrjBS47j1Yj-lW1IP1z_vp5Efnw-AqrMF3wD28JMRNyk6VuIe3togyoykoDIXGk_-axRtY94aftjJ_o0fwsMGtLKkZbQPWXPEYtiZ14evlgB2v8rjmA7bFJquS2MsnkB6da4vjKA_TfWIJS8srN2NHl7ikLiwb0xPzVVUuliXnP4uSGlsvZ80ElhSU2VLi2iyhVLCncHIndH4GvaIs3AtgERXgcZqjohFSajeMhyKPzFQpbRGaqj4ELSEz05Q5p24bs6wr0FwRP0PiZxXxM9mHj92ci7rIx62jN9vzyRqBn2cr9uzDu-4ziir5X3ThkH44RkrOEZ_hJp_X59r9DjVhTA8GfRi0B71a_P97eXn7Xt7CfRSS7Ns4PXwFD3jFbxSJswm9xeVv9xrx1CJ_0zAug7O7lpVrTy4vUQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Omadacycline%3A+A+Novel+Oral+and+Intravenous+Aminomethylcycline+Antibiotic+Agent&rft.jtitle=Drugs+%28New+York%2C+N.Y.%29&rft.au=Zhanel%2C+George+G.&rft.au=Esquivel%2C+Jenine&rft.au=Zelenitsky%2C+Sheryl&rft.au=Lawrence%2C+Courtney+K.&rft.date=2020-02-01&rft.pub=Springer+International+Publishing&rft.issn=0012-6667&rft.eissn=1179-1950&rft.volume=80&rft.issue=3&rft.spage=285&rft.epage=313&rft_id=info:doi/10.1007%2Fs40265-020-01257-4&rft.externalDocID=10_1007_s40265_020_01257_4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-6667&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-6667&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-6667&client=summon